6185 Stock Overview
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
CanSino Biologics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$18.36 |
52 Week High | HK$39.00 |
52 Week Low | HK$14.80 |
Beta | 0.58 |
1 Month Change | 18.76% |
3 Month Change | 6.00% |
1 Year Change | -50.58% |
3 Year Change | -95.12% |
5 Year Change | n/a |
Change since IPO | -94.87% |
Recent News & Updates
Recent updates
Shareholder Returns
6185 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 3.6% | 5.7% | 3.6% |
1Y | -50.6% | -40.7% | -10.1% |
Price Volatility
6185 volatility | |
---|---|
6185 Average Weekly Movement | 9.5% |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.6% |
10% least volatile stocks in HK Market | 3.7% |
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,494 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
6185 fundamental statistics | |
---|---|
Market cap | HK$8.37b |
Earnings (TTM) | -HK$1.60b |
Revenue (TTM) | HK$385.82m |
11.8x
P/S Ratio-2.8x
P/E RatioIs 6185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6185 income statement (TTM) | |
---|---|
Revenue | CN¥357.08m |
Cost of Revenue | CN¥800.83m |
Gross Profit | -CN¥443.75m |
Other Expenses | CN¥1.04b |
Earnings | -CN¥1.48b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | -6.00 |
Gross Margin | -124.27% |
Net Profit Margin | -415.23% |
Debt/Equity Ratio | 46.5% |
How did 6185 perform over the long term?
See historical performance and comparison